MX362218B - Derivados de pentilentetrazol. - Google Patents
Derivados de pentilentetrazol.Info
- Publication number
- MX362218B MX362218B MX2013012850A MX2013012850A MX362218B MX 362218 B MX362218 B MX 362218B MX 2013012850 A MX2013012850 A MX 2013012850A MX 2013012850 A MX2013012850 A MX 2013012850A MX 362218 B MX362218 B MX 362218B
- Authority
- MX
- Mexico
- Prior art keywords
- anxiety
- individuals
- instance
- compounds
- pentylenetetrazole
- Prior art date
Links
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical class C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 title 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- 230000036506 anxiety Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010054196 Affect lability Diseases 0.000 abstract 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 206010021639 Incontinence Diseases 0.000 abstract 1
- 206010022998 Irritability Diseases 0.000 abstract 1
- 206010028813 Nausea Diseases 0.000 abstract 1
- 206010029333 Neurosis Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010043268 Tension Diseases 0.000 abstract 1
- 208000012886 Vertigo Diseases 0.000 abstract 1
- 230000003542 behavioural effect Effects 0.000 abstract 1
- 230000003920 cognitive function Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 abstract 1
- 230000008693 nausea Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 231100000889 vertigo Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161482533P | 2011-05-04 | 2011-05-04 | |
| PCT/US2012/036217 WO2012151343A1 (en) | 2011-05-04 | 2012-05-03 | Pentylenetetrazole derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013012850A MX2013012850A (es) | 2014-04-30 |
| MX362218B true MX362218B (es) | 2019-01-09 |
Family
ID=46178772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013012850A MX362218B (es) | 2011-05-04 | 2012-05-03 | Derivados de pentilentetrazol. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9453020B2 (enExample) |
| EP (1) | EP2705013B1 (enExample) |
| JP (3) | JP6092849B2 (enExample) |
| CN (1) | CN103635446B (enExample) |
| AU (3) | AU2012250776B2 (enExample) |
| CA (1) | CA2835018C (enExample) |
| DK (1) | DK2705013T3 (enExample) |
| ES (1) | ES2579319T3 (enExample) |
| IL (2) | IL229218A (enExample) |
| MX (1) | MX362218B (enExample) |
| WO (1) | WO2012151343A1 (enExample) |
| ZA (1) | ZA201408423B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9453020B2 (en) | 2011-05-04 | 2016-09-27 | Balance Therapeutics, Inc. | Substituted pentylenetetrazoles as GABA receptor activity modulators |
| US10688103B2 (en) * | 2014-04-15 | 2020-06-23 | Balance Therapeutics, Inc. | Methods for treating hypersomnia |
| WO2018209119A1 (en) | 2017-05-10 | 2018-11-15 | Emory University | Treatment of conditions associated with myotonic dystrophy |
| EP3574915A1 (en) * | 2018-05-29 | 2019-12-04 | Neovacs | Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity |
| CN112920193B (zh) * | 2021-02-07 | 2021-11-16 | 南通大学 | 一种灰黄霉素四唑衍生物及其制备方法 |
| CN112979665B (zh) * | 2021-02-07 | 2021-11-19 | 南通大学 | 一种灰黄霉素施密特重排衍生物及其制备方法 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3062720A (en) | 1959-05-20 | 1962-11-06 | Philips Roxane | Sustained release pharmaceutical tablet |
| US3247066A (en) | 1962-09-12 | 1966-04-19 | Parke Davis & Co | Controlled release dosage form containing water-swellable beadlet |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4160452A (en) | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4777049A (en) | 1983-12-01 | 1988-10-11 | Alza Corporation | Constant release system with pulsed release |
| US4663308A (en) | 1984-07-18 | 1987-05-05 | Medical College Of Ohio | Method of use of polymers containing cross-linked azo bonds for releasing therapeutic agents into the lower gastrointestinal tract |
| US4931279A (en) | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
| US4668506A (en) | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
| US4713244A (en) | 1985-08-16 | 1987-12-15 | Bausch & Lomb Incorporated | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent |
| GB2209937B (en) | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| CH679207A5 (enExample) | 1989-07-28 | 1992-01-15 | Debiopharm Sa | |
| CA2046830C (en) | 1990-07-19 | 1999-12-14 | Patrick P. Deluca | Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer |
| CH683149A5 (fr) | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
| GB9211268D0 (en) | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
| PL174772B1 (pl) | 1993-01-06 | 1998-09-30 | Kinerton Ltd | Kompozycja farmaceutyczna zawierająca jonowy konjugat cząsteczkowy |
| US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| KR100477070B1 (ko) * | 1994-03-25 | 2006-04-21 | 이소테크니카 인코포레이티드 | 중수소화작용에의한의약품의효능강화법 |
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US5612052A (en) | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
| US5877224A (en) | 1995-07-28 | 1999-03-02 | Rutgers, The State University Of New Jersey | Polymeric drug formulations |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| IL126422A (en) | 1996-04-23 | 2004-02-19 | Kinerton Ltd | Biodegradable acidic polylactic polymers and methods for their preparation |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| US5968895A (en) | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| US5893985A (en) | 1997-03-14 | 1999-04-13 | The Lincoln Electric Company | Plasma arc torch |
| IT1304152B1 (it) | 1998-12-10 | 2001-03-08 | Mediolanum Farmaceutici Srl | Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| WO2000059481A1 (en) | 1999-04-06 | 2000-10-12 | Pharmaquest Ltd. | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT |
| WO2001001964A2 (en) | 1999-06-23 | 2001-01-11 | Sedum Laboratories, Inc. | Ionically formulated biomolecule microcarriers |
| JP4303438B2 (ja) | 1999-08-18 | 2009-07-29 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | ペプチドの持続放出製剤 |
| DK1104760T3 (da) * | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler |
| WO2002058672A2 (en) | 2001-01-26 | 2002-08-01 | Debio Recherche Pharmaceutique S.A. | Microparticles of biodegradable polymer encapsulating a biologically active substance |
| JP2005511477A (ja) | 2001-03-19 | 2005-04-28 | プラエシス ファーマシューティカルズ インコーポレーテッド | 持続放出のための医薬調合物 |
| KR20040091100A (ko) | 2002-03-04 | 2004-10-27 | 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. | 운반체 펩타이드를 함유하는 서방형 의약 조성물 |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| CN101309917B (zh) * | 2005-10-06 | 2013-09-11 | 奥斯拜客斯制药有限公司 | 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂 |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| WO2007139818A2 (en) * | 2006-05-22 | 2007-12-06 | The Board Of Trustees Of The Leland Stanford Junior University | Pharmacological treatment of cognitive impairment |
| CA2661302A1 (en) * | 2006-08-16 | 2008-02-21 | Auspex Pharmaceuticals, Inc. | Preparation and utility of opioid analgesics |
| US8946206B2 (en) | 2010-12-17 | 2015-02-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for improving cognitive function |
| US9453020B2 (en) | 2011-05-04 | 2016-09-27 | Balance Therapeutics, Inc. | Substituted pentylenetetrazoles as GABA receptor activity modulators |
-
2012
- 2012-05-03 US US14/115,307 patent/US9453020B2/en active Active
- 2012-05-03 DK DK12724430.9T patent/DK2705013T3/en active
- 2012-05-03 MX MX2013012850A patent/MX362218B/es active IP Right Grant
- 2012-05-03 ES ES12724430.9T patent/ES2579319T3/es active Active
- 2012-05-03 CA CA2835018A patent/CA2835018C/en not_active Expired - Fee Related
- 2012-05-03 WO PCT/US2012/036217 patent/WO2012151343A1/en not_active Ceased
- 2012-05-03 EP EP12724430.9A patent/EP2705013B1/en not_active Not-in-force
- 2012-05-03 CN CN201280033481.5A patent/CN103635446B/zh not_active Expired - Fee Related
- 2012-05-03 JP JP2014509425A patent/JP6092849B2/ja not_active Expired - Fee Related
- 2012-05-03 AU AU2012250776A patent/AU2012250776B2/en not_active Ceased
-
2013
- 2013-11-03 IL IL229218A patent/IL229218A/en active IP Right Grant
-
2014
- 2014-11-17 ZA ZA2014/08423A patent/ZA201408423B/en unknown
-
2016
- 2016-08-24 US US15/246,347 patent/US9951076B2/en not_active Expired - Fee Related
- 2016-10-28 IL IL248589A patent/IL248589A/en active IP Right Grant
-
2017
- 2017-02-09 JP JP2017022380A patent/JP2017105821A/ja active Pending
- 2017-08-25 AU AU2017219099A patent/AU2017219099B2/en not_active Ceased
-
2018
- 2018-09-20 JP JP2018176044A patent/JP2019006819A/ja active Pending
-
2019
- 2019-08-06 AU AU2019213325A patent/AU2019213325A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL229218A (en) | 2016-11-30 |
| CN103635446A (zh) | 2014-03-12 |
| US20170044165A1 (en) | 2017-02-16 |
| CA2835018C (en) | 2020-04-21 |
| JP2019006819A (ja) | 2019-01-17 |
| ES2579319T3 (es) | 2016-08-09 |
| EP2705013A1 (en) | 2014-03-12 |
| JP6092849B2 (ja) | 2017-03-08 |
| US9453020B2 (en) | 2016-09-27 |
| JP2017105821A (ja) | 2017-06-15 |
| MX2013012850A (es) | 2014-04-30 |
| NZ617347A (en) | 2015-11-27 |
| AU2017219099B2 (en) | 2019-05-30 |
| AU2012250776A1 (en) | 2013-12-05 |
| EP2705013B1 (en) | 2016-03-30 |
| IL248589A0 (en) | 2016-12-29 |
| CN103635446B (zh) | 2016-02-03 |
| ZA201408423B (en) | 2016-09-28 |
| US9951076B2 (en) | 2018-04-24 |
| CA2835018A1 (en) | 2012-11-08 |
| IL248589A (en) | 2017-09-28 |
| JP2014513130A (ja) | 2014-05-29 |
| AU2019213325A1 (en) | 2019-08-22 |
| HK1195050A1 (zh) | 2014-10-31 |
| US20140343040A1 (en) | 2014-11-20 |
| IL229218A0 (en) | 2014-01-30 |
| AU2017219099A1 (en) | 2017-09-14 |
| DK2705013T3 (en) | 2016-07-18 |
| AU2012250776B2 (en) | 2017-06-15 |
| WO2012151343A1 (en) | 2012-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1117045T1 (el) | Ενωσεις κινουκλιδινης ως προσδετες του νικοτινικου υποδοχεα ακετυλχολινης αλφα-7 | |
| MX2013012850A (es) | Derivados de pentilentetrazol. | |
| PH12012502373A1 (en) | Aminopyrimidine derivatives as lrrk2 modulators | |
| MX348606B (es) | Derivados de aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2). | |
| MX2014006026A (es) | Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2). | |
| MX356644B (es) | Derivados de 2-fenilaminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2) para el tratamiento de la enfermedad de parkinson. | |
| MX2020013099A (es) | Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina. | |
| MX2010006230A (es) | Derivados de arilamida substituidos con triazol y su uso como antagonistas de receptor purinergico p2x3 y/o p2x2/3. | |
| EA201390971A1 (ru) | ИМИДАЗО[5,1-f][1,2,4]ТРИАЗИНЫ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ | |
| HRP20130614T1 (en) | Novel pyrazole-substituted arylamides | |
| IN2014CN03250A (enExample) | ||
| TW201129565A (en) | Tricyclic heterocyclic compounds, compositions and methods of use thereof | |
| GEP20084551B (en) | 4-phenylamino-quinazolin-6-yl-amides | |
| TW200740773A (en) | Diaminopyrimidines as P2X3 and P2X2/3 modulators | |
| TN2011000339A1 (en) | Poly (adp-ribose) polymerase (parp) inhibitors | |
| MY183977A (en) | Cytotoxic benzodiazepine derivatives | |
| JO3116B1 (ar) | مشتق بيرازولوكينولين كمثبطات ل pde9 | |
| SG195085A1 (en) | Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors | |
| MX2011006843A (es) | Dihidropiridona-amidas como moduladores de p2x7. | |
| NZ600874A (en) | Fluorinated derivatives of deferiprone | |
| PT2139334E (pt) | Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos | |
| MX2009003645A (es) | Azaciclilaminas n-sustituidas como antagonistas de histamina-3. | |
| MX370017B (es) | Compuestos de [1,2,4]triazolo[1,5-c]quinazolin-5-amina heterobiciclo-sustituidos con propiedades antagonistas para a2a. | |
| MX2015004285A (es) | Derivado de imidazol. | |
| MX350862B (es) | Acidos de piperidinil naftilacetico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |